Andreas Busch
CIK 1775029 · Chief Innovation Officer · last filed 2026-03-16
Andreas Busch is a Chief Innovation Officer who has filed 21 SEC Form 4 insider transactions across 2 companies since 2019. The most recent filing shows the insider bought $229.0K of ABSI on Mar 16, 2026. Across all open-market trades the lifetime net is +$924.8K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $4.6M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CYCN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
18105 SE MILL PLAIN BLVD
VANCOUVER, WA 98683
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ABSI | Chief Innovation Officer | 421,446 | $10.91 | $4.60M | $381.0K | 14 | 2026-03-16 |
| Cyclerion Therapeutics, Inc. (CYCN) Delisted | Chief Scientific Officer | 1,819 | $23.52 | $42.8K | $543.8K | 7 | 2022-01-24 |
Recent Filings
21 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-16 | ABSI | Buy (P) | +100,000 | $229.0K | EDGAR |
| 2026-03-04 | ABSI | Tax (F) | −1,257 | -$3.5K | EDGAR |
| 2026-02-04 | ABSI | Tax (F) | −1,469 | -$4.4K | EDGAR |
| 2025-10-14 | ABSI | Tax (F) | −3,092 | -$11.4K | EDGAR |
| 2025-07-29 | ABSI | Buy (P) | +50,000 | $152.0K | EDGAR |
| 2025-03-04 | ABSI | Grant (A) | +23,700 | $0 | EDGAR |
| 2025-02-04 | ABSI | Tax (F) | −1,469 | -$5.4K | EDGAR |
| 2024-10-16 | ABSI | Tax (F) | −3,092 | -$12.6K | EDGAR |
| 2024-02-05 | ABSI | Grant (A) | +83,125 | $0 | EDGAR |
| 2023-10-16 | ABSI | Grant (A) | +175,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.